Skip to main content
. 2024 Feb 22;18(9):6845–6862. doi: 10.1021/acsnano.3c04471

Figure 2.

Figure 2

Combining NP-cGAMP and NP-MPLA enhances innate immune activation, co-stimulatory molecule expression, and pro-inflammatory cytokine secretion in vitro. (A) In vitro evaluation of interferon activation in RAW-Dual reporter cells after treatment with indicated formulation for 24 h, cGAMP doses indicated on x-axis, MPLA dose for NP-MPLA dose matched to MPLA dose in cGAMP:MPLA 1:16 (mean ± SD; n = 3 biologically independent samples). (B) In vitro evaluation of NF-κB activation in RAW-Dual reporter cells after treatment with indicated formulation for 24 h, MPLA doses indicated on x-axis, cGAMP dose for NP-cGAMP dose matched to cGAMP dose in cGAMP:MPLA 16:1 (mean ± SD; n = 3 biologically independent samples). (C) Flow cytometric quantification of mean fluorescence intensity (MFI) of CD86 expression by BMDCs treated with indicated doses of NP-cGAMP, NP-MPLA, or a mixture of both NPs (n = 3 biologically independent samples). (D–G) Concentration of secreted IFN-β (D), IL-6 (E), TNF-α (F), and IL-1α (G) by BMDCs after treatment with indicated doses of NP-cGAMP, NP-MPLA, or a mixture of both NPs (n = 3 biologically independent samples).